세계의 제대혈 및 조직은행 시장 업계 보고서 : 시장 규모, 세분화, 예측(2025년)

EXECUTIVE SUMMARY

The first successful transplant using cord blood-derived hematopoietic stem cells was conducted in October 1988. Since then, significant advancements have been made in the field of umbilical cord blood research. To date, over 40,000 umbilical cord blood transplants (UCBTs) have been performed globally, treating a wide range of conditions including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders.

Cord blood storage began as a commercial service in the early 1990s, but it was not until 2008 that cord tissue storage was introduced commercially. The first company to offer this service was Taiwan's HealthBanks Biotech Company Ltd., followed by HealthBaby and Cryolife in Hong Kong in 2009. In the U.S., Cord Blood Registry (CBR) started offering cord tissue storage in July 2010. Today, nearly all U.S. cord blood banks and approximately one-third of global banks offer cord tissue storage services.

For placental banking, LifebankUSA began offering placental blood storage in 2006 and placental tissue storage in 2011. Americord Registry followed in September 2017 as the second U.S. bank to offer placental tissue banking. Internationally, a number of cord blood banks also provide placental blood and tissue storage services. Some have expanded into storing other stem cell types, such as dental pulp stem cells, with DentCell, a dental pulp stem cell bank, being controlled by Cryoholdco, the largest cord blood banking consolidator in Latin America. Additionally, a few banks have started storing adipose-derived stem cells.

The cord blood industry has experienced unprecedented levels of mergers and acquisitions (M&A) in recent years, leading to significant market consolidation, particularly in Europe, Latin America, and the U.S. The market is now predominantly controlled by a handful of large cord blood banking operators. This consolidation is notable given the rapid growth of the industry in the early 2000s. Significant consolidation has occurred in the U.S., Europe, Asia, and Latin America:

• PBKM FamiCord has acquired most of the European market, including merging with it largest competitor Vita34 and acquiring assets following Cryo-Save AG's 2019 bankruptcy.
• CooperSurgical has consolidated reproductive, newborn stem cell, and genetic services within the U.S., managing at least 1.1 million units.
• Cryoholdco has amassed stem cell banking assets across Latin America, including four in Mexico, two in Colombia, two in Brazil, and one in Peru, totaling an estimated 300,000 units.
• Sanpower Group dominates the Asian market through its ownership of Global Cord Blood Corporation and other assets across Southeast Asia, controlling over 1.2 million units.
• India, with its burgeoning population of 1.4 billion, rivals China in size, making up approximately 36% of the world's 7.8 billion people. LifeCell International is the leading stem cell bank in India, storing over 320,000 units.

This consolidation has spurred many cord blood banks to explore new stem cell storage options and expand their services to include fertility and reproductive services, genetic testing, and cell therapy applications. The therapeutic potential of cord blood, cord tissue, placental blood, and amniotic fluid has driven the proliferation of storage services for these biomaterials.

Many cord blood banks have now expanded their offerings to include:

• Reproductive and assisted fertility services
• Pre- and post-natal genetic testing
• Cell therapy product development

While the private sector consolidates, many public (nonprofit) cord blood banks, particularly in the U.S., are struggling financially. These banks spend between $1 million and $6 million annually on processing, testing, storage, and licensing technologies. Revenue from cord blood sales is relatively low, often supplemented by government subsidies, donations, and grants.

The umbilical cord blood and tissue market is composed of several segments:

• 1. Storage (Cryopreservation) Market: This segment generates significant revenue from long-term storage contracts. Major investment firms have recently entered this market by acquiring stakes in cord blood banking companies.
• 2. Transplantation Medicine: There is a robust market for using cord blood in treating diseases such as leukemia and sickle cell disease. Over 40,000 UCB transplants have been performed, and the U.S. FDA has approved over 80 medical conditions for treatment using hematopoietic stem cells (HSCs) from cord blood.
• 3. Regenerative Medicine: Research into cord blood and tissue for regenerative medicine is growing. Studies from the mid-2000s have shown the potential of cord blood for treating neurological disorders. For instance, clinical trials have demonstrated the safety and effectiveness of minimally manipulated cord blood in treating conditions like cerebral palsy and autism. RheinCell Therapeutics, now owned by Catalent, has achieved GMP certification for manufacturing cord blood-derived iPSCs for cell therapy.
• 4. Research Supply Products: There is a growing market for research products derived from cord blood and tissue, including cells, tissues, reagents, and kits. Leading market players like Lonza, STEMCELL Technologies, and AllCells are major contributors to this sector.

This report provides insights into the following:

• The number of cord blood units stored globally, in both public and private banks.
• The number of hematopoietic stem cell transplants performed using cord blood cells.
• Utilization of cord blood in regenerative medicine clinical trials.
• Trends in cord blood use for HSCTs since 2005.
• Emerging technologies impacting the financial stability of public cord blood banks.
• Future opportunities for companion products derived from cord blood.
• The evolving landscape of cord blood banking.
• Expansion and extension of services by cord blood banks.
• Economic models and cost analyses for public and private cord blood banks.
• Pricing for processing and storage in private banks.
• Comparative analysis of cord blood processing technologies and their merits.
• Number and types of clinical trials and patents related to cord blood and tissue.
• Transplantation data from different cord blood registries.

The report also answers key questions such as:

• Strategies for improving the financial stability of public cord blood banks.
• Companion products developed from cord blood.
• Costs and revenues associated with processing and storing cord blood.
• Comparative pricing and revenue for cord blood units in different regions.
• Accreditation systems and processing technologies for cord blood banks.
• Utilization rates and research focus areas for cord blood and tissue-derived cells.

This comprehensive report provides a detailed analysis of the cord blood and tissue banking market, including historical data and future projections through 2032. It covers storage, processing technologies, market leaders, and recent M&A activity, market size metrics, forecasts, and so much more.

TABLE OF CONTENTS

1. REPORT OVERVIEW

• 1.1. Statement of the Report
• 1.2. Executive Summary
• 1.3. Introduction

2. CORD BLOOD & CORD BLOOD BANKS: AN OVERVIEW

• 2.1. Composition of a Cord Blood Sample
• 2.2. Cord Blood Banks
  • 2.2.1. Public Cord Blood Banks
    • 2.2.1.1. WMDA Registry on Global Cord Blood Units
    • 2.2.1.2. Public Cord Blood Banks in the U.S.
    • 2.2.1.3. Public Cord Blood Banks in Major European Countries
    • 2.2.1.4. Economic Model of Public Cord Blood Banks
    • 2.2.1.5. Cost Analysis for Public Cord Blood Banks
    • 2.2.1.6. Relationship between Cost and Release Rates
  • 2.2.2. Private Cord Blood Banks
    • 2.2.2.1. Private Cord Blood Banks in the U.S.
    • 2.2.2.2. World's Top Ten Private Cord Blood Banks by Size of Inventory
    • 2.2.2.3. Processing and Storage Charges in Private Cord Blood Banks, U.S.
    • 2.2.2.4. Processing & Storage Charges in Private Banks in Europe
    • 2.2.2.5. Processing and Storage Fee Charged by LifeCell (India)
    • 2.2.2.6. Processing & Storage Fees Charged by Global Cord Blood Corp. (China)
    • 2.2.2.7. Cost Analysis for Private Cord Blood Banks
    • 2.2.2.8. Revenue Generation by Private Cord Blood Banks
    • 2.2.2.9. Status and Noteworthy Features of Some U.S. Private Cord Blood Banks
    • 2.2.2.10. Public vs. Private Cord Blood Banks
  • 2.2.3. Hybrid Cord Blood Banks
    • 2.2.3.1. Proportion of Public, Private and Hybrid Cord Blood Banks
  • 2.2.4. Community Cord Blood Banks
• 2.3. Percent Share of Parents Storing Cord Blood by Country (Top 10)
• 2.4. The Unique Benefits of Cord Blood Transplant

3. CORD BLOOD BANK ACCREDITATIONS

• 3.1. Association for the Advancement Blood and Biotherapies (AABB)
  • 3.1.1. AABB Accreditation Phases and Expectations
• 3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
  • 3.2.1. FACT Standards
  • 3.2.3. FACT Accreditation Process
• 3.3. FDA-Registered Cord Blood Banks
• 3.4. FDA Biologics Application for Cord Blood
• 3.5. Investigation New Drug (IND) for Cord Blood
• 3.6. Human Tissue Authority (HTA)
• 3.7. Therapeutic Goods Act (TGA)

4. PATENT LANDSCAPE OF CORD BLOOD, CORD TISSUE & PLACENTA

• 4.1. Patents on Umbilical Cord Blood Stem Cells
  • 4.1.1. Legal Status of Cord Blood Stem Cell Patents
  • 4.1.2. Umbilical Cord Blood Stem Cell Patent Applications by Year
  • 4.1.3. Cord Blood Stem Cell Patent Applications by Jurisdiction
  • 4.1.4. Umbilical Cord Blood Stem Cell Patent Applicants
  • 4.1.5. Umbilical Cord Blood Stem Cell Inventors
  • 4.1.6. Owners of Umbilical Cord Blood Stem Cell Patents
• 4.2. Patents of Umbilical Cord Tissue
  • 4.2.1. Legal Status of Cord Tissue Patents
  • 4.2.2. Umbilical Cord Tissue Patent Applications by Year
  • 4.2.3. Umbilical Cord Tissue Patent Applications by Jurisdiction
  • 4.2.4. Umbilical Cord Tissue Patent Applicants
  • 4.2.5. Inventors of Umbilical Cord Tissue Patents
  • 4.2.6. Owners of Umbilical Cord Tissue Patents
• 4.3. Patents on Placental Tissue
  • 4.3.1. Placental Tissue Patent Applicants
  • 4.3.2. Placental Tissue Patent Applications by Year
  • 4.3.3. Placental Tissue Patents by Jurisdiction
  • 4.3.4. Inventors of Placental Tissue Patents
  • 4.3.5. Owners of Placental Tissue Patents
  • 4.3.6. Legal Status of Placental Tissue Patents
• 4.4. Patents on Cord Blood Expansion
  • 4.4.1. Number of Cord Blood Expansion Patent Applications by Year
  • 4.4.2. Cord Blood Expansion Patent Applications by Jurisdiction
  • 4.4.3. Legal Status of Cord Blood Expansion Patents
  • 4.4.4. Inventors of Cord Blood Expansion Patents
  • 4.4.5. Owners of Cord Blood Expansion Patents

5. UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS

• 5.1. Number of Papers Published on Umbilical Cord Blood (UCB)
• 5.2. Number of Papers Published in PubMed.gov on Umbilical Cord Tissue
• 5.3. Number of Papers Published on Placental Tissue
• 5.4. Published Papers on Cord Blood Expansion Methods

6. CLINICAL TRIAL DATA

• 6.1. Clinical Trials Using Umbilical Cord Blood Units (CBUs)
  • 6.1.1. Number of Umbilical Cord Blood Clinical Trials by Study Type
  • 6.1.2. Number of Cord Blood Clinical Trials by Phase of Study
  • 6.1.3. Number of Cord Blood Clinical Trials by Funder Type
  • 6.1.4. Diseases Addressed by Ongoing Cord Blood Clinical Trials
  • 6.1.5. Companies Participating in Cord Blood Clinical Trials, April 18, 2025
• 6.2. Clinical Trials using Umbilical Cord Tissue
  • 6.2.1. Umbilical Cord Tissue Clinical Trials by Phase of Study
  • 6.2.2. Umbilical Cord Tissue Clinical Trials by Funder Type
  • 6.2.3. Umbilical Cord Tissue Clinical Trials Sponsored by Companies
• 6.3. Placental Tissue Stem Cells in Clinical Trials
  • 6.3.1. Placental Tissue Stem Cells in Clinical Trials by Phase of Study
• 6.4. Clinical Trials using Expanded Cord Blood
  • 6.4.1. Major Participants in Expanded Cord Blood Clinical Trials

7. CORD BLOOD PROCESSING TECHNOLOGIES

• 7.1. The Process of Separation of Cord Blood Stem Cells
  • 7.1.1. Plasma Depletion (MaxCell Process)
  • 7.1.2. Density Gradient
  • 7.1.3. Hetastarch (HES)
  • 7.1.4. PrepaCyte-CB
  • 7.1.5. SEPAX
  • 7.1.6. AutoXpress (AXP)
  • 7.1.7. TotiCyte
  • 7.1.8. MacoPress Smart
• 7.2. Performance Comparison of Cord Blood Processing Technologies
• 7.3. Days to Neutrophil Engraftment by Processing Technology
• 7.4. Anticoagulants used in Cord Blood Processing
• 7.5. Cryopreservation of Umbilical Cord Blood
• 7.6. Bioprocessing of Umbilical Cord Tissue
• 7.7. Cord Blood Expansion Technologies
  • 7.7.1. Umbilical Cord Blood Expansion Strategies
    • 7.7.1.1. Aryl Hydrocarbon Antagonists
    • 7.7.1.2. Pyrimidoindole Derivatives
    • 7.7.1.3. Nicotinamide
    • 7.7.1.4. Notch Ligands
    • 7.7.1.5. Copper Chelator
    • 7.7.1.6. Valproic acid

8. CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW

• 8.1. Number of Cord Blood Donors & CBUs Available Worldwide
• 8.2. CBUs Available by Geography
• 8.3. Cord Blood Units (CBUs) Registered in U.S. Registries
  • 8.3.1. Cord Blood Units (CBUs) in the U.S. by Race and Ethnicity as of 2024
• 8.4. CBUs Available in Europe
• 8.5. CBUs Available in Asia/Pacific
• 8.6. HLA Typing of Unrelated Cord Blood Donors and CBUs Worldwide
  • 8.6.1. Unrelated BM, PB and CB HSCs Shipped Worldwide
  • 8.6.2. Global Exchange of Cord Blood Units (CBUs)
• 8.7. WMDA's Search & Match Service
  • 8.7.1. Number of Searches made in WMDA Registry for CBUs by Year
  • 8.7.2. Yield of Search Results from WMDA Registry, 2017-2023

9. INDICATIONS FOR UBC TRANSPLANTATION

• 9.1. Advantages of Cord Blood Stem Cells
  • 9.1.1. Hematopoietic Properties of Cord Blood Stem Cells
  • 9.1.2. Immune Properties of Cord Blood Stem Cells
  • 9.1.3. Impact of HLA Mismatch in UCB Transplant Recipients
• 9.2. Malignant Indications Addressable by UCB Transplantation
• 9.3. Non-Malignant Indications for CBU Transplantation
• 9.4. Application of UCB in Regenerative Medicine

10. CORD BLOOD: A TRANSPLANT MEDICINE

• 10.1. Worldwide PB, BM & CB Transplants Compared
• 10.2. Cord Blood Stem Cells Transplantation by Geography
  • 10.2.1. CBU Transplantations in Asia
  • 10.2.2. UCB Transplants in North America
  • 10.2.3. UCB Transplants in Europe
  • 10.2.4. UCB Transplants in Oceania
  • 10.2.5. CBU Transplants in South America
• 10.3. Cost of UCB Transplantation
  • 10.3.1. Complications through 1-Year Post HSCT

11. CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE

• 11.1. Autism
• 11.2. Cerebral palsy
• 11.3. Alzheimer's Disease
• 11.4. Diabetes
• 11.5. Heart Diseases
• 11.6. Multiple Sclerosis
• 11.7. Stroke

12. MARKET ANALYSIS

• 12.1. Umbilical Cord Blood Banking Services Market
  • 12.1.1. Umbilical Cord Blood (UCB) Banking Market Share by Geography, 2024
  • 12.1.2. Public vs. Private Cord Blood Banking Service Market
  • 12.1.3. Global Market Share for Cord Blood & Cord Tissue Banking Services
  • 12.1.4. Market Share of CB for Transplantation & Regenerative Medicine
  • 12.1.5. Percent Share of Cord Blood & Cord Tissue Market by Indication
• 12.2. Global Market for Umbilical Cord Tissue Banking Service
• 12.3. Historical Revenue Analysis of the Cord Blood Industry
• 12.4. Geographical Revenue Variations in Cord Blood Banking
• 12.5. Innovations Impacting Cord Blood Banking Revenue
• 12.6. Growth Drivers for the Cord Blood Industry

13. PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS

• 13.1. AllCells
  • 13.1.1. Research Use Only (RUO) Products
    • 13.1.1.1. Mobilized Leukopak
    • 13.1.1.2. Leukopak
    • 13.1.1.3. Bone Marrow
    • 13.1.1.4. Cord Blood
    • 13.1.1.5. Whole Blood
  • 13.1.2. GMP Products
    • 13.1.2.1. Clinical Grade Mobilized Leukopak
    • 13.1.2.2. Clinical Grade Leukopak
    • 13.1.2.3. Clinical Grade Bone Marrow
  • 13.1.3. Isolated Cell Products
    • 13.1.3.1. CD34+ HSPCs
    • 13.1.3.2. T Cells
    • 13.1.3.3. NK Cells
    • 13.1.3.4. Monocytes
    • 13.1.3.5. B Cells
    • 13.1.3.6. PBMCs (MNCs)
• 13.2. AlphaCord
  • 13.2.1. Prices
• 13.3. Americord Registry, Inc.
• 13.4. Angiocrine Bioscience
  • 13.4.1. Proprietary E-CEL Platform
• 13.5. Anja Health Personalized Cord Blood Banking
  • 13.5.1. Anja's Mannual Processing of Cord Blood
• 13.6. Anthony Nolan
  • 13.6.1. Products & Services
    • 13.6.1.1. Cell Isolation & Purification
    • 13.6.1.2. Cell Culture & Expansion
• 13.7. Baylx, Inc.
  • 13.7.1. Core Technology
  • 13.7.2. Product Piupeline
• 13.8. NMDPSM
  • 13.8.1. NMDP Network
• 13.9. Biocell Center
• 13.10. BioEden
  • 13.10.1. Dental Pulp Cells
  • 13.10.2. Differences between Dental Pulp Cells and Cord Blood Cells
• 13.11. BioIntegrate, LLC
  • 13.11.1. GeneXSTEM Injectables
• 13.12. Bloodworks Northwest
  • 13.12.1. Products & Services
• 13.13. California Umbilical Cord Collection Program
  • 13.13.1. Participating Locations
• 13.14. Carolinas Cord Blood Bank (CCBB)
• 13.15. Celaid Therapeutics
  • 13.15.1. In Vitro Expansion Technology
  • 13.15.2. Business Model
• 13.16. Celebration Stem Cell Centre (CSCC)
  • 13.16.1. Products
• 13.17. Cell Care
• 13.18. Cellenkos, Inc.
  • 13.18.1. Technology
  • 13.18.2. Cellenkos' Pipeline
• 13.19. Cells4Life Group LLP
  • 13.19.1. Cellsplus
  • 13.19.2. TotiCyte Processing Technology
  • 13.19.3. Cord Blood Releases from Cells4Life
• 13.20. CellSave Arabia
  • 13.20.1. Cord Blood Stem Cell Banking Services
  • 13.20.2. Stem Cell Banking Price
• 13.21. Celularity, Inc.
• 13.22. Center for International Blood and Marrow Transplant Research (CIBMTR)
• 13.23. CHOC Blood Bank
• 13.24. Cleveland Cord Blood Center
  • 13.24.1. Research on Diabetic Retinopathy
  • 13.24.2. Research on Type I Diabetes
  • 13.24.3. Research on Parkinson's disease
  • 13.24.4. Research on Wound Healing
• 13.25. ClinImmune Cell and Gene Therapy
  • 13.25.1. FDA Licensed Cord Blood
  • 13.25.2. Gene Therapy
  • 13.25.3. Cellular Therapies
• 13.26. Cord Blood Bank of Arkansas (CBBA)
• 13.27. Cord Blood Center Group
• 13.28. Cord Blood Registry (CBR)
  • 13.28.1. Business Experience
  • 13.28.2. Licensing & Accreditation
  • 13.28.3. Pricing
• 13.29. Cord for Life
  • 13.29.1. Technology: PremierMax
• 13.30. CordLife Group, Ltd.
  • 13.30.1. Accreditations & Certifications
  • 13.30.2. Services
  • 13.30.3. Cordlife Group's Network
  • 13.30.4. Cordlife's Market
• 13.31. CordVida
• 13.32. Crioestaminal
  • 13.32.1. Cord Blood Transplantation in Portugal
• 13.33. Cryo-Cell International, Inc.
  • 13.33.1. Processing Technology
  • 13.33.2. Recovery of Viable CFU by PrepaCyte-CB
  • 13.33.3. Cryo-Cell International's Revenue Generation
  • 13.33.4. Cryo-Cell International's Pricing
• 13.34. CryoCyte, LLC
• 13.35. CryoHoldco LATAM
• 13.36. Cryopoint
• 13.37. Cryoviva Biotech Pvt., Ltd.
• 13.38. DKMS gGMBH
  • 13.38.1. Cord Blood Units
  • 13.38.2. Services
  • 13.38.3. DKMS' Donor Typing Profile & Active Donors
• 13.39. Duke University School of Medicine
  • 13.39.1. Ducord (HPC Cord Blood)
• 13.40. European Society for Blood and Bone Marrow Transplantation (EBMT)
  • 13.40.1. EBMT Transplant Activity
• 13.41. Ever Supreme Bio Technology, Co., Ltd.
  • 13.41.1. Allogeneic UMSC01
  • 13.41.2. New Research
• 13.42. ExCellThera
  • 13.42.1. ECT-001 Cell Therapy
• 13.43. FamiCord Group
• 13.44. Fate Therapeutics, Inc.
  • 13.44.1. FT1050 - Stem Cell Modulator
• 13.45. Future Health
  • 13.45.1. Locations of Laboratories
  • 13.45.2. Business Experience
  • 13.45.3. Collection Kit
  • 13.45.4. Transportation Container
  • 13.45.5. Processing Method
  • 13.45.6. Components Stored
  • 13.45.7. Storage Methods
  • 13.45.8. Licensing & Accreditation
  • 13.45.9. Prices
  • 13.45.10. Additional Services
• 13.46. Gamida Cell
  • 13.46.1. OMIDUBICELL
• 13.47. GeneCell
• 13.48. Global Cord Blood Corporation (GCBC)
  • 13.48.1. GCBC's Revenue Generation
• 13.49. Glycostem Therapeutics
  • 13.49.1. Science and Technology
  • 13.49.2. oNKord
  • 13.49.3. viveNK
  • 13.49.4. uNiK Production Process
• 13.50. Hawaii Cord Blood Bank
• 13.51. HealthBaby
  • 13.51.1. Service Plans
  • 13.51.2. 18-Year Cord Blood (HSCs) Storage Plan
  • 13.51.3. 18-Year CordBasic Umbilical Cord Lining Storage Plan
  • 13.51.4. CellOptima CordPlus Umbilical Cord Lining Storage
• 13.52. HealthBanksUSA
  • 13.52.1. BioArchive Cryogenic Storage System
  • 13.52.2. AXP Cord Blood Processing
• 13.53. HEMAFUND
• 13.54. Hemogenyx Pharmaceuticals
  • 13.54.1. Technology
• 13.55. IMMUNIQUE
• 13.56. Insception LifeBank
  • 13.56.1. Cord Blood Releases from Insception LifeBank
  • 13.56.2. Cord Blood Cells Released for Regenerative Medicine from Insception
• 13.57. JP McCarthy Cord Stem Cell Bank
• 13.58. Kangstem Biotech, Co., Ltd.
  • 13.58.1. GD11 Brand
  • 13.58.2. Core Technology
• 13.59. LifebankUSA
• 13.60. LifeCell International Pvt. Ltd.
• 13.61. Life Line Stem Cell
• 13.62. LifeSouth Cord Blood Bank
  • 13.62.1. Accreditation & Hospital Partners
• 13.63. Magenta Therapeutics
  • 13.63.1. Magenta's Cord Blood-Based Clinical Trial
• 13.64. Maze Cord Blood
• 13.65. Medipost, Co., Ltd.
  • 13.65.1. Medipost's Product & Products in Development
    • 13.65.1.1. CARTISTEM
    • 13.65.1.2. PNEUMOSTEM
    • 13.65.1.3. SMUP-IA-01
• 13.66. MD Anderson Cord Blood Bank
• 13.67. Mesoblast, Ltd.
  • 13.67.1. Mesoblast's UCB-Based Clinical Trial
• 13.68. MiracleCord, Inc.
  • 13.68.1. AXP II Automated Processing
  • 13.68.2. StemCare Collection Kit
  • 13.68.3. Cost of Cord Blood Banking
• 13.69. Mononuclear Therapeutics, Ltd.
  • 13.69.1. MonoTx Cord Blood Bank
  • 13.69.2. MonoTx's Pipeline
  • 13.69.3. Products
    • 13.69.3.1. Human Cord Blood Mononuclear Cells (MNCs)
    • 13.69.3.2. Exosome Rich Plasma (ERP)
    • 13.69.3.3. Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)
• 13.70. New England Cord Blood Bank, Inc.
  • 13.70.1. Cord Blood Processing
  • 13.70.2. Cord Blood & Tissue Storage
• 13.71. New York Blood Center
  • 13.71.1. Blood Products & Services
  • 13.71.2. Cell Therapies
  • 13.71.3. Cord Blood
• 13.72. OrganaBio
  • 13.72.1. OrganaBio's Proprietary Supply Chains
  • 13.72.2. Perenatal Tissues
• 13.73. PacifiCord
  • 13.73.1. FDA-Approved Sterile Collection Bags
  • 13.73.2. AXP Processing System
  • 13.73.3. BioArchive System
• 13.74. Plasticell Ltd.
  • 13.74.1. CombiCult Technology
  • 13.74.2. Hematopoietic Stem Cell Expansion
• 13.75. ReeLabs Pvt. Ltd.
• 13.76. Restem, LLC
  • 13.76.1. Clinical Trial for COVID-19
  • 13.76.2. Clinical Trial for Muscular Dystrophy
  • 13.76.3. Clinical Trial for Idiopathic Inflammatory Myositis (IIM)
  • 13.76.4. Clinical Trial for Heart Failure
• 13.77. San Diego Cord Blood Bank
• 13.78. Saneron CCEL Therapeutics, Inc.
  • 13.78.1. U-CORD-CELL Program
  • 13.78.2. SERT-CELL Program
• 13.79. SmartCells
• 13.80. SSM Cardinal Glennon Children's Medical Center
  • 13.80.1. ALLOCORD
• 13.81. Stembanc, Inc.
  • 13.81.1. Popular Packages from Stembanc
• 13.82. Stem Cell Cryobank, Inc.
• 13.83. StemCyte, Inc.
  • 13.83.1. Services
  • 13.83.2. Add On Services
  • 13.83.3. StemCyte in Clinical Trials
  • 13.83.4. StemCyte's Plans & Pricing
• 13.84. Throne Biotechnologies, Inc.
  • 13.84.1. Effects of CB-SCs in Diabetics
  • 13.84.2. Effects of CB-SCs on Alopecia Areata
• 13.85. Transcell Biolife
  • 13.85.1. ScellCare
  • 13.85.2. ToothScell
• 13.86. Upstate Cord Blood Bank
• 13.87. ViaCord
  • 13.87.1. ViaCord's Complete Services
  • 13.87.2. Cord Blood + Tissue Banking
  • 13.87.3. Newborn Digestive Health
  • 13.87.4. Newborn DNA Guardian
• 13.88. Versity, Inc.
• 13.89. Vita 34 AG (Recently Merged with Famicord)
  • 13.89.1. Revenue Generation by Vita 34 AG
• 13.90. Vitalant Clinical Services
  • 13.90.1. Hospital Services
  • 13.90.2. Laboratory Services
  • 13.90.3. Research
• 13.91. World Marrow Donor Association (WMDA)
  • 13.91.1. WMDA Search & Match Service
• 13.92. Worldwide Network for Blood & Marrow Transplantation (WBMT)

APPENDIX

• APPENDIX 1: Advancements in Umbilical Cord Blood Banking
• Appendix 1.1: Market Growth and Trnds
• Appendix 1.2: Advances in Automation and Cryopreservation
• Appendix 1.3: Advances in Isolation Methods
• Appendix 1.4: Expanding Applications of CBUs
• Appendix 1.5: Potential of Artificial Intelligence (AI) in UCB Banking

INDEX OF FIGURES

• FIGURE 2.1: Schematic Cross-Sectional View of Umbilical Cord
• FIGURE 2.2: Percent Utilization of HSCs by Type in Pediatric Patients
• FIGURE 2.3: Composition of a Cord Blood Sample
• FIGURE 2.4: World's Top Ten Private Cord Blood Banks by Inventory Size
• FIGURE 2.5: Revenue Generation in Three Major Private Cord Blood Banks, 2017-2024
• FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks
• FIGURE 2.7: Percent Share of Parents Storing Cord Blood in Top Ten Countries
• FIGURE 4.1: Legal Status of Umbilical Cord Blood Stem Cell Patents
• FIGURE 4.2: Number of Applications for Umbilical Cord Blood Stem Cells, 2000-2024
• FIGURE 4.3: Legal Status of Cord Tissue Patents
• FIGURE 4.4: Umbilical Cord Tissue Patent Applications, 2000-2024
• FIGURE 4.5: Placental Tissue
• FIGURE 4.6: Placental Tissue Patent Applications by Year
• FIGURE 4.7: Cord Blood Expansion Patent Applications by Year
• FIGURE 5.1: Number of Papers on Umbilical Cord Blood in PubMed.gov, 2000-2024
• FIGURE 5.2: Number of Papers Published in PubMed.gov on Cord Tissue, 2000-2024
• FIGURE 5.3: Number of Published Papers on Placental Tissue, 2000-2024
• FIGURE 5.4: Published Papers on Cord Blood Expansion in PubMed.gov
• FIGURE 6.1: Percent Share of UCB Clinical Trials by Study Type, April 18, 2025
• FIGURE 6.2: Percent Share of Cord Blood Clinical Trials by Phase of Study, April 18, 2025
• FIGURE 6.3: Percent Share of Cord Blood Clinical Trials by Funder Type, April 18, 2025
• FIGURE 6.4: Percent Share of Studies Addressing Various Diseases, April 18, 2025
• FIGURE 6.5: Umbilical Cord Tissue Clinical Trials by Phase of Study, April 19, 2025
• FIGURE 6.6: Umbilical Cord Tissue Clinical Trials, April 19, 2025
• FIGURE 6.7: Placental Stem Cells in Clinical Trials by Phase of Study, April 19, 2025
• FIGURE 7.1: The Buffy Coat of Cord Blood after Centrifugation
• FIGURE 7.2: Cord Blood Sample Bag after Plasma Depletion
• FIGURE 7.4: PrepaCyte-CB System
• FIGURE 7.5: SEPAX
• FIGURE 7.6: AutoXpress
• FIGURE 7.7: TotiCyte Processing Steps
• FIGURE 7.9: Percent Viable Stem Cells in the Processed Cord Blood by Technology
• FIGURE 7.10: Days to Neutrophil Engraftment by Technology
• FIGURE 7.11: Stem Cell (CD34+) and Nucleated White Cell Count with CPD and Heparin
• FIGURE 7.12: A Comparative Analysis with Three Different Cryoprotectants
• FIGURE 8.1: Number of CB Donors and CBUs available Worldwide, 1997-2024
• FIGURE 8.2: Cord Blood Units (CBUs) Registered in the U.S. Registries by Year, 2001-2024
• FIGURE 8.3: HLA Typing of Unrelated Cord Blood Donors and CBUs Worldwide
• FIGURE 8.4: HSCs of BM, PB and CB Shipped Worldwide, 1997-2023
• FIGURE 8.5: Global Exchange of CBUs, 2023
• FIGURE 8.6: Number of Searches made in WMDA Registry for CBUs, 2017-2023
• FIGURE 8.7: Yield of Search Results from WMDA Registry, 2017-2023
• FIGURE 9.1: Percent Utilization of PB, BM and CB Worldwide, 1997-2023
• FIGURE 10.1: Worldwide PB, BM & CB Transplants Compared
• FIGURE 10.2: CBU Transplantations in Asia, 1999-2003
• FIGURE 10.3: UCB Transplants in North America
• FIGURE 10.4: CUB Transplants in Europe
• FIGURE 10.5: UCB Transplants in Oceania
• FIGURE 12.1: Global Cord Blood Banking Service Market, 2024-2032
• FIGURE 12.2: Percent Share of Cord Blood Service Market by Geography, 2024
• FIGURE 12.3: Public vs. Private Cord Blood Banking Service Market
• FIGURE 12.4: Global Market Share for Cord Blood & Cord Tissue Banking Services, 2024
• FIGURE 12.5: Market Share of CB for Transplantation & Regenerative Medicine
• FIGURE 12.6: Percent Share of Cord Blood & Cord Tissue Market by Indication
• FIGURE 13.1: Funders for CIBMTR in 2023
• FIGURE 13.2: Sales Revenues and Gross Profits for CordLife, 2014-2023
• FIGURE 13.3: Cryo-Cell International's Revenue Generation, 2017-2023
• FIGURE 13.4: GCBC's Revenue Generation, 2015-2022
• FIGURE 13.5: Revenue Generation by Vita 34 AG, 2014-2021
• FIGURE App.1.1: Proportion of Clinical Conditions Investigated using UCB-MSCs

INDEX OF TABLES

• TABLE 2.1: General Features of Public Cord Blood Banks
• TABLE 2.2: Number of CBUs in WMDA Registry
• TABLE 2.3: Public Cord Blood Banks in the U.S.
• TABLE 2.4: Public Cord Blood Banks in European Countries
• TABLE 2.5: International Prices of Cord Blood Unit (CBU)
• TABLE 2.6: Prices of CBUs in NMDP Banks in the U.S.
• TABLE 2.7: General Features of Private Cord Blood Banks
• TABLE 2.8: Leading Private Cord Blood Banks in the U.S.
• TABLE 2.9: World's Top Ten Private Cord Blood Banks by Inventory Size
• TABLE 2.10: Processing and Storage Charges in CBR (U.S.)
• TABLE 2.11: Processing and Storage Fee Charged by Vita34 (Europe)
• TABLE 2.12: Processing and Storage Fees Charged by LifeCell (India)
• TABLE 2.13: Processing & Storage Fees Charged by Global Cord Blood Corp. (China)
• TABLE 2.14: Revenue Generation by Three Major Private Cord Blood Banks, 2017-2024
• TABLE 2.15: Examples of Hybrid Cord Blood Banks
• TABLE 2.16: Percent Share of Parents Storing Cord Blood in Top Ten Countries
• TABLE 3.1: AABB Accredited Cord Blood Banks
• TABLE 3.2: Select FACT-Accredited Cord Blood Banks
• TABLE 4.1: Legal Status of Umbilical Cord Stem Cell Patents
• TABLE 4.2: Umbilical Cord Blood Stem Cell Patent Applications by Year
• TABLE 4.3: Umbilical Cord Blood Patent Applications by Jurisdiction
• TABLE 4.4: Applicants of Umbilical Cord Patents
• TABLE 4.5: Umbilical Cord Blood Stem Cell Patent Inventors
• TABLE 4.6: Owners of Umbilical Cord Blood Stem Cell Patents
• TABLE 4.7: Legal Status of Cord Tissue Patents
• TABLE 4.8: Number of Umbilical Cord Tissue Patent Applications, 2000-2024
• TABLE 4.9: Umbilical Cord Tissue Patent Applications by Jurisdiction
• TABLE 4.10: Umbilical Cord Tissue Patent Applicants
• TABLE 4.11: Umbilical Cord Tissue Patent Inventors
• TABLE 4.12: Owners of Umbilical Cord Tissue Patents
• TABLE 4.13: Placental Tissue Patent Applicants
• TABLE 4.14: Placental Tissue Patent Applications by Year
• TABLE 4.15: Placental Tissue Patent Jurisdictions
• TABLE 4.16: Inventors of Placental Tissue Patents
• TABLE 4.17: Owners of Placental Tissue Patents
• TABLE 4.18: Legal Status of Placental Tissue Patents
• TABLE 4.19: Cord Blood Expansion Patent Applications by Year
• TABLE 4.20: Cord Blood Expansion Patent Applications by Jurisdiction
• TABLE 4.21: Legal Status of Cord Blood Expansion Patents
• TABLE 4.22: Inventors of Cord Blood Expansion Patents
• TABLE 4.23: Owners of the Cord Blood Expansion Patents
• TABLE 6.1: Total Number of Clinical Trials (CBU, CT, PT and Expanded CBU), Apr. 2025
• TABLE 6.2: Number of Umbilical Cord Blood Clinical Trials by Study Type, April 18, 2025
• TABLE 6.3: Number of Cord Blood Clinical Trials by Phase of Study, April 18, 2025
• TABLE 6.4: Number of Cord Blood Clinical Trials by Funder Type, April 18, 2025
• TABLE 6.5: Select Companies Sponsoring Cord Blood Clinical Trials
• TABLE 6.6: Umbilical Cord Tissue Clinical Trials by Phase of Study, April 19, 2025
• TABLE 6.7: Umbilical Cord Tissue Clinical Trials by Funder Type, April 19, 2025
• TABLE 6.8: Select Companies Sponsoring Cord Tissue Clinical Trials, April 19, 2025
• TABLE 6.9: Placental Tissue Stem Cells in Clinical Trials by Phase of Study, April 19, 2025
• TABLE 6.10: Major Clinical Trials Using Expanded Umbilical Cord Blood Cells
• TABLE 7.1: Umbilical Cord Blood Expansion Strategies
• TABLE 8.1: Umbilical Cord Blood Units Registered with WMDA, April 22, 2025
• TABLE 8.2: Number of CB Donors and CBUs available Worldwide, 1997-2024
• TABLE 8.3: Number of Cord Blood Donors and CBUs available by Geography, 2023
• TABLE 8.4: Available CBUs in the U.S. by Race & Ethnicity, September 30, 2024
• TABLE 8.5: CBUs Available in Europe as of April 23, 2025
• TABLE 8.6: CBUs Available in Asia/Pacific as of April 23, 2025
• TABLE 8.7: HSCs of BM, PB and CB Shipped Worldwide, 1997-2023
• TABLE 8.8: Number of Searches made in WMDA Registry for CBUs, 2017-2023
• TABLE 8.9: Yield of Search Results from WMDA Registry, 2017-2023
• TABLE 9.1: Malignant Indications Addressed by UCB Transplantation
• TABLE 9.2: Non-Malignant Indications for CUB Transplantation
• TABLE 9.3: Diseases Targeted by Cord Blood Cells as Regenerative Medicines
• TABLE 10.1: Worldwide PB, BM & CB Transplants Compared
• TABLE 10.2: CBU Transplantations by Geography, 1999-2023
• TABLE 10.3: Comparison of Median Cost during Admit for CB, PB and BM HSCTs
• TABLE 10.4: Complications through 1-Year Post HSCT
• TABLE 11.1: UCB & UCBT in Clinical Trials on Autism
• TABLE 11.2: A Sample List of Clinical Trials for Cerebral Palsy using CBUs
• TABLE 11.3: A Sample List of Clinical Studies for Alzheimer's Disease using CBUs
• TABLE 11.4: A Sample List of Clinical Studies for Diabetes using CBUs
• TABLE 11.5: A Small List of Clinical Studies for Heart Diseases using CBUs
• TABLE 11.6: A Short List of Clinical Studies for Multiple Sclerosis using CBUs
• TABLE 12.1: Global Cord Blood Banking Service Market, 2024-2032
• TABLE 12.2: Global Market for Cord Tissue Banking Service, 2024-2032
• TABLE 13.1: Angiocrine's R&D Pipeline
• TABLE 13.2: Baylx's hUC-MSC-Derived Product Pipeline
• TABLE 13.3: NMDP Network of Cord Blood Banks
• TABLE 13.4: Cell Care's Pricing for Cord Blood Processing and Storage
• TABLE 13.5: Cellenkos' Product Pipeline
• TABLE 13.6: Cord Blood Releases from Cells4Life
• TABLE 13.7: Celularity's Active Clinical Pipeline
• TABLE 13.8: Recovery of Viable CFU by PrepaCyte-CB
• TABLE 13.9: Cryo-Cell International's Revenue Generation, 2017-2023
• TABLE 13.10: Cryo-Cell International's Pricing
• TABLE 13.11: CryoCyte's Option Plans & Pricing
• TABLE 13.12: DKMS' Donor Typing Profile & Active Donors
• TABLE 13.13: EBMT Transplant Activity, 2023
• TABLE 13.14: Cord Blood Banking Cost in GeneCell
• TABLE 13.15: GCBC's Revenue Generation, 2015-2022
• TABLE 13.16: Glycostem's Product Pipeline
• TABLE 13.17: Insception LifeBank's Pricing
• TABLE 13.18: Cord Blood Releases from Insception LifeBank for Transplantation
• TABLE 13.19: Cord Blood Cells Released for Regenerative Medicine from Insception
• TABLE 13.20: Kangstem's Sponsor Initiated Clinical Trials
• TABLE 13.21: LifeCell International's Pricing
• TABLE 13.22: Maze Cord Blood: Banking Cost
• TABLE 13.23: MiracleCord's Cord Blood Banking Cost
• TABLE 13.24: MonoTx's Product Pipeline